Safety Profile:

• Most common adverse reaction was fever
• All adverse reactions were mild or moderate

Method:

• Randomized, double-blind, placebo-controlled
• Phase 1: healthy adults (aged 18-80, split up into two groups -- 18-59 and 60+; tested negative for IgM/IgG antibodies) were given either the vaccine or a placebo over a two-dose schedule (2, 4, or 8 micrograms)
• Phase 2: healthy adults were given either vaccine or placebo over a single-dose schedule (8 micrograms) or two-dose schedule (4 micrograms)

Performance:

• Humoral response was seen on day 42 for everyone who received the vaccine
• The two-dose sequence with 4 micrograms was significantly more effective than the single 8 microgram or 4 microgram dose